More Stories

Informist, Tuesday, Feb. 3, 2026

 

Please click here to read all liners published on this story

--Mankind Pharma Oct-Dec consol net profit INR 4.09 bln 
--Analysts saw Mankind Pharma Oct-Dec consol net profit at INR 4.76 bln 
--Mankind Pharma Oct-Dec consol revenue INR 35.67 bln 
--Analysts saw Mankind Pharma Oct-Dec consol revenue at INR 35.73 bln 
--Mankind Pharma Oct-Dec consol PAT INR 4.09 bln vs INR 3.80 bln year ago 
--Mankind Pharma Oct-Dec consol revenue INR 35.67 bln vs INR 31.99 bln yr ago 
--Mankind Pharma Oct-Dec labour codes implementation cost INR 1.07 bln 
--Mankind Pharma Apr-Dec consol PAT INR 13.59 bln vs INR 15.70 bln yr ago 
--Mankind Pharma Apr-Dec consol sales INR 108.35 bln vs INR 91.28 bln yr ago 
--Mankind Pharma Oct-Dec consol EBITDA INR 8.16 bln vs INR 8.19 bln yr ago 
--Mankind Pharma Oct-Dec consol EBITDA margin 22.9% vs 25.6% year ago 
--Mankind Pharma Oct-Dec consol gross margin 72.6% vs 70.9% year ago 
--Mankind Pharma Q3 revenue from exports INR 5.21 bln vs INR 4.57 bln yr ago 
--Mankind Pharma Oct-Dec domestic ops revenue INR 30.46 bln vs INR 27.42 bln

 

By Astha Oriel

 

MUMBAI – Mankind Pharma Ltd. reported a high single-digit year-on-year increase in its consolidated bottom line for the December quarter. The company's net profit was, however, below Street estimates due to a one-time cost arising from the implementation of labour codes. The company reported a double-digit on-year growth in its top line for the quarter.

 

The company's net profit for the December quarter was INR 4.09 billion, up nearly 8% on year but down 20% on quarter. Analysts had estimated the company's net profit to be INR 4.76 billion. The company incurred a one-time cost of INR 1.07 billion, of which INR 741 million is due to the implementation of labour codes, INR 190 million is due to costs related to intellectual property rights, and the remaining is from an asset impairment provision. Without the one-time cost, the company's net profit would have been INR 5.15 billion, above analysts' estimates. This is the first on-year increase in net profit in five quarters.

 

The company's revenue from operations was INR 35.67 billion, up nearly 12% on year but down nearly 4% on quarter. Analysts had estimated the company's revenue from operations at INR 35.73 billion. This is the 12th consecutive quarter of year-on-year increase in the company's revenue.

 

The company's total expenditure in the December quarter was INR 30.28 billion, up over 8% on year but down more than 4% on quarter. The on-year rise in expenditure was because of a 13% rise in other expenses to INR 8.46 billion and 17% on-year increase in costs related to employee benefits to INR 8.24 billion. The cost for raw materials consumed was up nearly 4% on year at INR 5.53 billion. This is the first time in 12 quarters that the company's total expenditure has increased in single digit year on year.

 

The company's adjusted earnings before interest, tax, depreciation, and amortisation was INR 8.16 billion, flat on year and down nearly 12% on quarter. The EBITDA margin contracted by 270 basis points to 22.9% from 25.6% a year ago.

 

The company's revenue from domestic operations was INR 30.46 billion. Exports contributed INR 5.21 billion to the company's overall revenue. The growth in revenue was driven by base business, as well as consolidation of Bharat Serum and Vaccines Ltd. business, the company said. The company's revenue from consumer healthcare business grew more than 5% on year. The share of modern trade and e-commerce increased to 13.1% in the December quarter, the company said. The company's consolidated gross margin expanded by 170 bps to 72.6% from 70.9% in the year-ago quarter.

 

For the nine-month period of Apr-Dec, the company's consolidated net profit was INR 13.59 billion and the revenue was INR 108.35 billion. Shares of Mankind Pharma Tuesday closed at INR 2,162.60 on the National Stock Exchange, up nearly 5% from the previous session. The earnings were announced after the close of stock markets.  End

 

Edited by Ashish Shirke

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.